Friday, September 29, 2023


Biotechnology News Magazine

RELiZORB ® – Alcresta Therapeutics Announces Series of Commercial Milestone Achievements

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

RELiZORB ®: Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced a series of commercial milestone achievements.

Alcresta Therapeutics announced its first profitable year in 2021, the completion of royalty payments to the Cystic Fibrosis Foundation (CFF) and a doubling of its sales force to expand the promotion of RELiZORB, a first-of-its-kind digestive enzyme cartridge used in enteral feeding designed to mimic the function of pancreatic lipase. RELiZORB is the only enzyme product cleared by the FDA for use in enteral feeding.

Payer access to RELiZORB has improved significantly over the last two years, resulting in 70% growth year-over-year in net sales with 24% adjusted EBITDA.  In December 2013, CFF granted to Alcresta a research award to support the research program that resulted in RELiZORB. As part of the grant agreement, Alcresta agreed to pay certain royalties and milestone payments over time. The rapid net sales growth allowed the company to complete its royalty obligation to CFF, which was an early supporter of the company’s platform. Alcresta’s final royalty payment to CFF was made in March 2022.

“Both broad payer access and profitability have allowed us to further invest to reach deeper into the population of CF patients who are enterally fed,” said Daniel Orlando, Chief Executive Officer at Alcresta Therapeutics.

Supporting this rapid growth is a recently expanded account manager team up from seven sales territories in one region to 16 territories in two regions. RELiZORB is currently used by approximately 23% of treatable patients within the cystic fibrosis total addressable market. Over the past 24 months, RELiZORB has been added as a covered benefit for most commercial payers and state Medicaids. This expanded access follows the recent favorable CMS/Medicare local coverage determination (LCD ID No. 38955) covering RELiZORB for patients who meet the coverage criteria for enteral nutrition and have a diagnosis of exocrine pancreatic insufficiency. The improved access allows the expanded sales team to accelerate execution of Alcresta’s commercial strategy to position RELiZORB as the standard of care for enterally fed patients with CF.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine